Global Myocardial Infarction Market Report by Drug Class (Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers,

Global Myocardial Infarction Market Report by Drug Class (Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers, Analgesics, Thrombolytics), Distribution Channels (Hospitals, Hospital Pharmacies, Drug Stores, Online Drug Stores), Regions and Company Analysis 2024-2032

Global Myocardial Infarction Market share was valued at US$ 2.02 Billion in 2023. It is anticipated to increase at a CAGR of 6.06% from 2024 to 2032 and be valued at US$ 3.43 Billion by 2032.

A myocardium's part that receives little or no blood flow is what causes myocardial infarction (MI), also referred to as a ""heart attack."" An MI could be ""silent"" and go unnoticed, or it could be a catastrophic occurrence that results in hemodynamic decline and abrupt death. The underlying cause of the majority of myocardial infarctions is coronary artery disease. Oxygen is not available to the myocardium when coronary artery blockage occurs. Long-term oxygen supply deprivation of the heart can result in necrosis and death of heart cells. Patients may exhibit pressure or discomfort in the chest that radiates to the jaw, arm, shoulder, or neck. Myocardial ischemia may be linked to elevated biochemical markers such cardiac troponins and abnormalities in the electrocardiogram in addition to the history and physical examination.

Global Myocardial Infarction Market Growth Trends
• In 2023, there will be 8 billion people on Earth! Of these, 620 million or more people worldwide suffer from circulatory and cardiac ailments. The British Heart Foundation estimates that 60 million people worldwide suffer from a heart or circulation ailment each year.
• An estimated 1 in 13 persons worldwide suffer from a heart or circulatory ailment. About one in three fatalities worldwide are caused by heart and circulation disorders. According to the British Heart Foundation, there will be 20.5 million deaths in 2021, or 56,000 deaths every day, or one death every 1.5 seconds.
• The rise in cases of heart attack and cardiovascular diseases is propelling the global myocardial infarction market.
• Moreover, another major driver driving growth in the worldwide myocardial infarction market is the increasing incidence of certain associated risk factors, such as high cholesterol, excessive alcohol use, smoking, inactivity, etc.
• According to a CDC report, high blood pressure, high cholesterol, and smoking are the three main risk factors for heart disease that over half of all Americans (47%) have at least one of those.
• Various initiatives are taken to raise awareness regarding heart attacks. This adds to the growth of the global myocardial infarction industry.
• The Global Heart Hub's 2023 Heart Failure Awareness Month Campaign seeks to raise public awareness of heart failure. Our goal is to increase public knowledge of heart failure's warning signs, symptoms, and risk factors—as well as the value of prompt diagnosis and appropriate treatment. This year's campaign, with the hashtag #HighlightHeartFailure, aims to save lives by raising awareness of heart failure.
• The threefold goals of the World Heart Federation (WHF) are to promote information exchange, translate science into policy, and unite and guide the CVD community. With the tagline ""Use Heart, Know Heart,"" World Heart Day 2023 provides a novel approach to spreading awareness by encouraging people to learn about their own cardiovascular health as well as the health of their friends, family, parents, and community.

United States Myocardial Infarction Market
• United Sates might hold a dominant position in the global myocardial infarction market. This is due to increase in product launches and approvals.
• In February 2024- Zydus Lifesciences Ltd. announced that the US health agency has given it final approval to produce and sell its generic Isosorbide Mononitrate extended-release tablets, which are intended to help patients with specific heart conditions avoid chest pain.
• In October 2023-Medinol declared that the FDA had approved its EluNIR-PERL drug-eluting stent (DES). Coronary heart disease is treated with this device.
• The growing number of people who are obese and the increase in incidences and prevalence of high rates of heart ailments are the main factors driving the myocardial infarction market expansion in this region.
• In 2022- states had an adult obesity rate at or over 35%, up from 19 states the year before, according to TFAH's analysis of the most recent data from the Behavioral Risk Factor Surveillance System of the Centers for Disease Control and Prevention (CDC). 10 years ago, not a single state had an adult obesity rate of 35% or more.
• 41.9 percent of adults in the country are obese. Adults who identify as Black or Latino had the greatest rates of obesity (44.9 percent and 45.6%, respectively).
• Cardiovascular disease (CVD) continues to be the top cause of mortality in the United States, accounting for 928,741 deaths in 2020, according to the American Heart Association.
• Coronary heart disease (CHD) accounted for 41.2% of all fatalities in the US in 2020 due to cardiovascular disease (CVD). Stroke (17.3%), other CVD (16.8%), high blood pressure (12.9%), heart failure (9.2%), and artery disorders (2.6%), round out the top five causes.

Global Myocardial Infarction Industry News

Pfizer, Sanofi-Aventis/Bristol-Myers Squibb, AstraZeneca, Daiichi Sankyo, Eli Lilly and Company, Takeda, Novartis, Genentech, Amgen, Regeneron/Sanofi, Boehringer Ingelheim, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, and Mesoblast are the leading companies in the global myocardial infarction market.
• In March 2024 - The FDA authorized Novo Nordisk's weight-loss medication Wegovy in order to lower the risk of major cardiovascular problems in individuals with heart disease and obesity.
• In April 2024 - Johnson & Johnson will present clinical and real-world data from its cardiovascular portfolio at the 73rd Annual Scientific Session & Expo of the American College of Cardiology. Eleven abstracts, including five oral presentations, will be presented at the event. They will discuss the therapeutic advantages of novel medications, such XARELTO® (rivaroxaban), and innovative technologies, like those from Abiomed® and Biosense Webster®, for the treatment of cardiovascular disorders.
• In November 2023 - Eli Lilly and Company's ZepboundTM (tirzepatide) injectable was approved by the U.S. Food and Drug Administration (FDA). This is the first and only obesity medication of its kind that stimulates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) hormone receptors.
• In June 2023 - The first anti-inflammatory medication for treating cardiovascular disease, colchicine, is approved by the FDA.
• In November 2022 - Johnson & Johnson has agreed to buy Abiomed, a supplier of cardiovascular solutions, for USD 16.6 Billion. Following the completion of the deal, Abiomed will function as a distinct business and enhance Johnson & Johnson MedTech's standing as a rising cardiovascular innovation. This will improve patient outcomes and raise the bar for treatment for heart failure, one of the deadliest illnesses.

Drug Class – Market breakup in 9 viewpoints:

1. Antiplatelet Agents
2. Glycoprotein IIb/IIIa Inhibitors
3. Antithrombotic Agents
4. Beta-adrenergic Blockers
5. Vasodilators
6. Angiotensin-converting Enzyme (ACE) Inhibitors
7. Angiotensin-receptor Blockers
8. Analgesics
9. Thrombolytics

Distribution Channel – Market breakup in 4 viewpoints:

1. Hospitals
2. Hospital Pharmacies
3. Drug Stores
4. Online Drug Stores

Countries – Market breakup of 25 Countries:

1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 UAE
5.3 South Africa

All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis

Company Analysis:

1. Pfizer
2. Sanofi-Aventis/Bristol-Myers Squibb
3. AstraZeneca
4. Merck
5. Daiichi Sankyo
6. Eli Lilly and Company
7. Takeda
8. Novartis
9. Genentech
10. Amgen
11. Regeneron/Sanofi
12. Boehringer Ingelheim
13. Idorsia Pharmaceuticals
14. Faraday Pharmaceuticals
15. CSL Behring
16. Immediate Therapeutics
17. Mitsubishi Chemical Group
18. Kancera
19. Bayer
20. Recardio
21. Mesoblast